Holistic Financial Partners Sells 1,751 Shares of AstraZeneca PLC (NASDAQ:AZN)

Holistic Financial Partners lessened its position in AstraZeneca PLC (NASDAQ:AZN) by 30.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,080 shares of the company’s stock after selling 1,751 shares during the period. Holistic Financial Partners’ holdings in AstraZeneca were worth $318,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AZN. Martin Investment Management LLC lifted its position in AstraZeneca by 2.8% during the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after buying an additional 7,615 shares in the last quarter. Integrated Advisors Network LLC lifted its position in shares of AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after purchasing an additional 13,860 shares in the last quarter. Creative Planning grew its stake in shares of AstraZeneca by 8.0% during the third quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after purchasing an additional 16,692 shares during the last quarter. Northcape Wealth Management LLC acquired a new stake in shares of AstraZeneca in the second quarter valued at approximately $269,000. Finally, Cetera Advisors LLC raised its position in AstraZeneca by 124.5% in the 1st quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock worth $6,657,000 after purchasing an additional 54,488 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Down 2.8 %

Shares of NASDAQ AZN opened at $63.23 on Monday. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The stock has a market cap of $196.05 billion, a P/E ratio of 30.25, a P/E/G ratio of 1.17 and a beta of 0.47. The firm has a 50 day moving average price of $75.03 and a 200 day moving average price of $78.23.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.87 EPS. Analysts expect that AstraZeneca PLC will post 4.07 EPS for the current year.

Analyst Ratings Changes

AZN has been the topic of a number of recent research reports. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.